Cargando…

Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals

Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and bioch...

Descripción completa

Detalles Bibliográficos
Autores principales: Truyens, Marie, De Ruyck, Elodie, Gonzales, Gerard Bryan, Bos, Simon, Laukens, Debby, De Vos, Martine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471955/
https://www.ncbi.nlm.nih.gov/pubmed/34575218
http://dx.doi.org/10.3390/jcm10184107
_version_ 1784574600476098560
author Truyens, Marie
De Ruyck, Elodie
Gonzales, Gerard Bryan
Bos, Simon
Laukens, Debby
De Vos, Martine
author_facet Truyens, Marie
De Ruyck, Elodie
Gonzales, Gerard Bryan
Bos, Simon
Laukens, Debby
De Vos, Martine
author_sort Truyens, Marie
collection PubMed
description Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and biochemical remission under treatment with immunomodulators or biologicals were included. Fatigue, physical tiredness and depression were assessed using the fatigue Visual Analogue Scale (fVAS), the Shortened Fatigue Questionnaire (SFQ) and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), respectively. Relevant clinical and biochemical parameters were included in regression analyses to identify factors associated with physical fatigue. Results: In total, 157 IBD patients were included. Up to 45.9% of patients reported fatigue, physical tiredness was observed in 51% and depression in 10.8%. The majority of patients with subclinical depression were fatigued. Female sex (OR = 4.17 [1.55–6.78], p = 0.002) was independently associated with physical fatigue. Transferrin saturation (OR = −0.11 [−0.22–−0.007], p = 0.037) and treatment with adalimumab (compared to infliximab, OR = −3.65 [−7.21–−0.08], p = 0.045) entailed a lower risk of fatigue. Conclusion: Fatigue is observed in about half of IBD patients in remission and can be a symptom of underlying undetected depression. Sex, transferrin saturation and medication were identified as independent risk factors.
format Online
Article
Text
id pubmed-8471955
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84719552021-09-28 Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals Truyens, Marie De Ruyck, Elodie Gonzales, Gerard Bryan Bos, Simon Laukens, Debby De Vos, Martine J Clin Med Article Background: Although highly prevalent among inflammatory bowel disease (IBD) patients, fatigue remains an unmet clinical need. The aim was to describe the prevalence of fatigue in an IBD population in remission and identify factors associated with fatigue. Methods: IBD patients in clinical and biochemical remission under treatment with immunomodulators or biologicals were included. Fatigue, physical tiredness and depression were assessed using the fatigue Visual Analogue Scale (fVAS), the Shortened Fatigue Questionnaire (SFQ) and the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), respectively. Relevant clinical and biochemical parameters were included in regression analyses to identify factors associated with physical fatigue. Results: In total, 157 IBD patients were included. Up to 45.9% of patients reported fatigue, physical tiredness was observed in 51% and depression in 10.8%. The majority of patients with subclinical depression were fatigued. Female sex (OR = 4.17 [1.55–6.78], p = 0.002) was independently associated with physical fatigue. Transferrin saturation (OR = −0.11 [−0.22–−0.007], p = 0.037) and treatment with adalimumab (compared to infliximab, OR = −3.65 [−7.21–−0.08], p = 0.045) entailed a lower risk of fatigue. Conclusion: Fatigue is observed in about half of IBD patients in remission and can be a symptom of underlying undetected depression. Sex, transferrin saturation and medication were identified as independent risk factors. MDPI 2021-09-11 /pmc/articles/PMC8471955/ /pubmed/34575218 http://dx.doi.org/10.3390/jcm10184107 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Truyens, Marie
De Ruyck, Elodie
Gonzales, Gerard Bryan
Bos, Simon
Laukens, Debby
De Vos, Martine
Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title_full Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title_fullStr Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title_full_unstemmed Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title_short Prevalence of Fatigue and Unrecognized Depression in Patients with Inflammatory Bowel Disease in Remission under Immunosuppressants and Biologicals
title_sort prevalence of fatigue and unrecognized depression in patients with inflammatory bowel disease in remission under immunosuppressants and biologicals
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471955/
https://www.ncbi.nlm.nih.gov/pubmed/34575218
http://dx.doi.org/10.3390/jcm10184107
work_keys_str_mv AT truyensmarie prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals
AT deruyckelodie prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals
AT gonzalesgerardbryan prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals
AT bossimon prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals
AT laukensdebby prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals
AT devosmartine prevalenceoffatigueandunrecognizeddepressioninpatientswithinflammatoryboweldiseaseinremissionunderimmunosuppressantsandbiologicals